Use of gonadotropin-releasing hormone (GnRH) agonists produces a trans
ient increase and subsequent long-term reduction in concentrations of
pituitary hormones, resulting in gonadal hormone suppression. This rev
ersible suppression is useful in treating diseases dependent on these
hormones. GnRH agonists have been approved for use in patients with en
dometriosis, advanced prostate cancer, and precocious puberty. As rese
arch continues, GnRH agonists are expected to change the clinical appr
oach to the treatment of many other reproductive and nonreproductive d
iseases.